Christopher G. Bunick

1 week ago | dermatologytimes.com | Marie Bosslett |Christopher G. Bunick

Patients with moderate to severe chronic hand eczema (CHE) suffer from a pressing therapeutic gap as no FDA-approved treatments exist, and delgocitinib (LEO Pharma) has not yet been approved in the United States. In an interview with Dermatology Times, Christopher G.

2 weeks ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, delved into the evolving treatment landscape of atopic dermatitis (AD). Bunick shared key insights on the distinct mechanisms of action behind emerging biologics and highlighted the ongoing need to raise the bar in achieving optimal treatment outcomes—particularly itch relief and skin clearance.

3 weeks ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, broke down the implications of the pivotal LEVEL UP trial for patients with atopic dermatitis (AD). According to Bunick, the study not only reinforced the value of measuring multiple treatment outcomes simultaneously but also introduced a new bar for success that all future therapies should aim to meet.

1 month ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In an interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, offered perspective on where investigational biologics targeting the OX40 and OX40 ligand (OX40L) pathway may eventually fit into the already complex atopic dermatitis (AD) treatment landscape. “It’s a complicated atopic dermatitis landscape right now,” Bunick said. “We obviously have the oral JAK inhibitors.

1 month ago | dermatologytimes.com | Emma Andrus |Christopher G. Bunick

In a recent interview with Dermatology Times, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine, shared insights into the evolving science of biologics for atopic dermatitis (AD)—specifically, the emerging therapeutic potential of targeting the OX40/OX40 ligand pathway. According to Bunick, a critical limitation of current biologic therapies lies in their "monotargeted" approach.